DaVita, Inc. (NYSE:DVA)

CAPS Rating: 3 out of 5

The Company is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease.

Recs

0
Player Avatar buckpower (89.00) Submitted: 8/29/2006 12:22:54 AM : Outperform Start Price: $58.88 DVA Score: +30.95

diabetes is a problem in the US and they help those with diabetes

Featured Broker Partners


Advertisement